CDK4 and liposarcoma: Alternatively, indirectly supporting the data suggesting CDK4 inhibition as suitable therapeutic strategy for sarcoma, in a phase 1 clinical trial, flavopiridol and doxorubicin combination therapy resulted in a disease control rate of 67% in progressive non-chemotherapy-responsive liposarcoma with likely CDK4 amplification [80].